Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:EFA NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEFAiShares MSCI EAFE ETF$92.10+0.0%$89.18$72.14▼$92.49$66.42B0.8614.52 million shs10.72 million shsNVSNovartis$125.01+0.8%$118.91$96.06▼$125.62$264.08B0.621.98 million shs1.03 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEFAiShares MSCI EAFE ETF-0.11%+2.33%+4.22%+4.07%+14.64%NVSNovartis-0.19%+4.57%+8.52%+10.38%+8.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEFAiShares MSCI EAFE ETFN/AN/AN/AN/AN/AN/AN/AN/ANVSNovartis1.8786 of 5 stars1.03.02.50.03.40.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEFAiShares MSCI EAFE ETF 0.00N/AN/AN/ANVSNovartis 2.09Hold$123.50-1.21% DownsideCurrent Analyst Ratings BreakdownLatest NVS and EFA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025NVSNovartisMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$123.00(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEFAiShares MSCI EAFE ETFN/AN/AN/AN/AN/AN/ANVSNovartis$55.19B4.79$10.77 per share11.61$21.59 per share5.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEFAiShares MSCI EAFE ETFN/AN/A16.48∞N/AN/AN/AN/AN/ANVSNovartis$11.94B$6.8718.2014.191.7425.64%41.08%16.83%11/4/2025 (Estimated)Latest NVS and EFA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/17/2025Q2 2025NVSNovartis$2.38$2.42+$0.04$2.06$13.94 billion$14.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEFAiShares MSCI EAFE ETF$2.572.79%N/AN/AN/ANVSNovartis$2.592.07%N/A37.70%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEFAiShares MSCI EAFE ETFN/AN/AN/ANVSNovartis0.530.820.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEFAiShares MSCI EAFE ETF79.80%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipEFAiShares MSCI EAFE ETFN/ANVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEFAiShares MSCI EAFE ETFN/A721.20 millionN/ANot OptionableNVSNovartis75,8832.11 billion2.11 billionOptionableNVS and EFA HeadlinesRecent News About These CompaniesCorient IA LLC Buys Shares of 5,000 Novartis AG (NYSE:NVS)August 19 at 6:52 AM | marketbeat.comCresset Asset Management LLC Has $13.13 Million Stake in Novartis AG (NYSE:NVS)August 19 at 6:16 AM | marketbeat.comNovartis AG (NYSE:NVS) Shares Purchased by Kovitz Investment Group Partners LLCAugust 19 at 5:25 AM | marketbeat.comNovartis AG (NYSE:NVS) Shares Sold by Boston PartnersAugust 19 at 5:01 AM | marketbeat.comEthic Inc. Trims Position in Novartis AG (NYSE:NVS)August 18 at 6:01 AM | marketbeat.comVirtu Financial LLC Decreases Position in Novartis AG (NYSE:NVS)August 18 at 4:29 AM | marketbeat.comBenjamin Edwards Inc. Sells 32,839 Shares of Novartis AG (NYSE:NVS)August 18 at 4:09 AM | marketbeat.comDeutsche Bank AG Raises Holdings in Novartis AG (NYSE:NVS)August 18 at 3:37 AM | marketbeat.comNew Novartis ESC data highlights strength of cardiovascular portfolioAugust 18 at 2:15 AM | globenewswire.comMassive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the StormAugust 17 at 7:23 PM | fool.comRep. Lisa C. McClain Sells Novartis AG (NYSE:NVS) SharesAugust 17 at 11:11 AM | marketbeat.comDimensional Fund Advisors LP Purchases 422,869 Shares of Novartis AG (NYSE:NVS)August 17 at 6:28 AM | marketbeat.comNeuberger Berman Group LLC Sells 3,737 Shares of Novartis AG (NYSE:NVS)August 17 at 5:31 AM | marketbeat.comFox Run Management L.L.C. Purchases 3,351 Shares of Novartis AG (NYSE:NVS)August 16 at 8:44 AM | marketbeat.comCookson Peirce & Co. Inc. Takes $24.76 Million Position in Novartis AG (NYSE:NVS)August 16 at 7:53 AM | marketbeat.comHighTower Advisors LLC Has $26.52 Million Position in Novartis AG (NYSE:NVS)August 16 at 4:45 AM | marketbeat.com2 Dividend Stocks to Buy and HoldAugust 15, 2025 | msn.comNational Bank of Canada FI Reduces Stake in Novartis AG (NYSE:NVS)August 15, 2025 | marketbeat.comMondrian Investment Partners LTD Lowers Position in Novartis AG (NYSE:NVS)August 14, 2025 | marketbeat.comNovartis AG (NYSE:NVS) Shares Purchased by Citigroup Inc.August 14, 2025 | marketbeat.comNovartis AG (NYSE:NVS) Shares Sold by Callan Family Office LLCAugust 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVS and EFA Company DescriptionsiShares MSCI EAFE ETF NYSEARCA:EFA$92.10 +0.01 (+0.01%) Closing price 04:10 PM EasternExtended Trading$92.12 +0.02 (+0.02%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares MSCI EAFE ETF, formerly iShares MSCI EAFE Index Fund (the Fund), is an exchange-traded fund. The Fund's investment objective is to seek investment results that correspond to the price and yield performance of its underlying index, MSCI EAFE Index (the Index). The Index has been developed by MSCI Inc. as an equity benchmark for its international stock performance. The Index includes stocks from Europe, Australasia and the Far East. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors.Novartis NYSE:NVS$125.01 +1.00 (+0.81%) Closing price 03:59 PM EasternExtended Trading$122.33 -2.68 (-2.15%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Home Depot Holds Gains After Narrow Q2 Misses Medtronic: The Opportunity Gets Healthier for Income Investors Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s End Micron Stock Still Cheap Despite 25% Rally, Analysts Say Qualcomm Just Passed 1 Major Test, But Can It Pass the Next? D-Wave Buying Spree: Will These Firms Be Potential Targets? Lyft's Billion-Dollar Signal: Why Wall Street Is Betting Big Can AI Defense Contracts Push Palantir Shares Higher? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access